{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Ubrelvy Untitled Letter – A Double Fault for AbbVie? Or Makeup Misread for FDA?",
    "url": "https://www.lexblog.com/2024/09/17/ubrelvy-untitled-letter-a-double-fault-for-abbvie-or-makeup-misread-for-fda/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-9M0WGD6C",
        "url": "https://www.lexblog.com/lib/9M0WGD6C/"
    },
    "datePublished": "2024-09-17T14:38:38-04:00",
    "dateModified": "2024-09-17T11:39:15-04:00",
    "author": {
        "@type": "Person",
        "name": "Dominick DiSabatino, Cortney Inman"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Sheppard, Mullin, Richter & Hampton LLP"
    },
    "organizationScope": "at-publication",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.fdalawblog.com/?p=2218",
    "sourceStability": "may-move"
}